Additionally, in a myeloma cell line resistant to AZ12908010 with a gatekeeper mutation in the FGFR3 gene, a secondary gatekeeper mutation was identified, resulting in the development of cross-resistance to two other FGFR inhibitors, AZD4547 and PD173074 [227]. The gene discussed is FGFR3; the disease is plasma cell myeloma.